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EDITORIAL
Clinical and daily respiratory care and clinical trials within the COVID-19 era
Zuzana Diamant a,b,c, Leif Bjermer a and Vibeke Backer d
aDepartment of Respiratory Medicine and Allergology, Institute for Clinical Science, Skane University Hospital, Lund University, Lund,
Sweden; bDepartment of Respiratory Medicine, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic;
cDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen,
Netherlands; dCentre for Physical Activity Research, Rigshospitalet and Copenhagen University, Copenhagen, Denmark
Since December 2019, the SARS-CoV-2 infection has
flooded the entire world and consequently, redirected
our focus towards treatment of the acute sequelae of
COVID-19 disease, the adjusted organization of the
outpatient care, the prevention of further spreading,
and the (re)search for effective treatment options.
Currently, both the community and the health care
providers (HCPs) are facing a growing list of attention
points on a daily basis. In support of the HCPs, the
Danish Society for Respiratory Medicine has published
a Guideline for management of COVID-19 disease
during hospital admission in a non-intensive care set-
ting in this journal (Weinreich ECRJ2020).
Although the vast majority of COVID-19-related
symptoms and signs are usually mild to moderate and
eventually self-limiting, susceptible individuals may
develop pneumonia, sometimes accompanied by pul-
monary embolism, resulting in respiratory failure often
accompanied with multi-organ involvement. Among
patients who end up at the ICU, the mortality rate is
high [1]. While individuals with chronic respiratory
diseases such as allergy, asthma and COPD are generally
at risk of virally induced (severe) exacerbations [2],
interestingly, these populations seemed under-
represented among those with severe-COVID-19 disease
in the initial reports from China [3,4]. However, more
recent reports from the USA COVID-NET hospitals
show chronic lung disease as an underlying condition
in approximately 30% of hospitalized patients with
COVID-19 [5], while especially those with COPD
appeared at risk [6]. Additionally, immunocompromised
patients, including the elderly (i.e., over 65 years old),
patients with diabetes mellitus or those on (systemic)
corticosteroids in conjunction with underlying immune
disorders, may be at increased risk of being infected and
more severely affected by SARS-CoV-2 [3,7].
These initial observations raised many questions
regarding the use of immunosuppressants such as corti-
costeroid-containing controllers. However, optimal dis-
ease control is the cornerstone of defense against
respiratory triggers, including infections and allergens,
in patients with chronic airway disease including allergic
rhinosinusitis and (allergic) asthma. Given the fact that
there is currently no evidence that topical corticosteroids
negatively affect the COVID-19 outcome and in line with
other professional societies within the respiratory and
allergy field, e.g. AAAAI, ERS, GINA, NAEPP and
NICE, NORA underscores the importance of adequate
disease control – especially since spring pollen season has
started in Northern Hemisphere. Apart from the general
avoidance and hygiene measures issued by health autho-
rities, respiratory societies recommend that patients con-
tinue taking their controller medications including
corticosteroid-containing controllers and biologicals,
according to their personal treatment plan and to seek
medical help if disease control deteriorates [8–10]. These
recommendations are in place for both adults and chil-
dren with chronic inflammatory airway disease even if
infected by SARS-CoV-2 or suspected of having the infec-
tion. In line with the general recommendations, interac-
tions with HPCs should take place remotely, whenever
possible.
While the standard care consists of supportive treat-
ment, there is no approved (effective) treatment for
COVID-19 disease and all currently applied treatment
options – including chloroquine – are off-label, yield-
ing varying efficacy. New treatment strategies presently
ongoing are targeting virus replication (e.g., remdesivir,
favipiravir) [11] or the virus entering the cell (e.g., the
TMPRSS2 inhibitor, camostat mesylate) [12] or the
COVID-19-released sequelae including the pro-
inflammatory pathways (e.g. anti-TNF-alpha, anti-
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IL6) [11] or the excessive pulmonary vascular leakage
(e.g. Icatibant, a bradykinin antagonist or enoximone,
a PDE3-inhibitor) [13,14].
Apart from COVID-19-directed research, the pan-
demic has affected many ongoing non-COVID-19-
related clinical trials as most of them have been set on
hold. Clinical trials on COVID-19 should be prioritized
and quickly implemented following local regulatory
policies, however, it is also critical that other ongoing
clinical research, such as on new treatment modalities or
clinical assessments can safely continue whenever possi-
ble. However, restrictive measures issued by health
authorities which resulted in the close-down of clinical
units, public transportation, etc., hamper the implemen-
tation of certain protocol-related procedures including
scheduled visits. Nevertheless, with proper adjustments,
some studies can be continued without loss of safety or
data integrity. Regulators, including FDA and EMA,
recently issued recommendations how to safely handle
specific aspects of clinical research [15]. Whenever pos-
sible, validated mobile-apps or other tools as well as tele-
medicine can be implemented to replace onsite visits
after coordination with IRB/EC, sponsor, pharmacy,
research staff and participants, while all protocol devia-
tions should be properly documented. In case partici-
pants need to come onsite, proper measures and
precautions should be taken as issued by local regulators
and health authorities including staff wearing personal
protective equipment (PPE), the use of appropriate dis-
infectants and proper handling of any biological
samples.
With respect to lung function measurements,
bronchoprovocation testing and airway sampling pro-
cedures, aerosols may develop on exhalation, therefore,
most guidelines recommend to postpone these tests if
not strictly necessary. However, in case of need, lung
function measurements can be performed safely pro-
vided that adequate precautions are made [16].
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